Latest Investment News

CD Private Equity Fund II reported a steep decline in net profit for FY25, with earnings per unit plunging 98%, yet continued to deliver solid distributions to unitholders amid a challenging US private equity market.

CD Private Equity Fund III reported a remarkable 726.6% jump in net profit to $18.56 million for FY25, driven by strong fair value gains and portfolio realizations. The Fund declared a $0.20 per unit distribution amid ongoing geopolitical and market challenges.

CD Private Equity Fund I reported a 43% decline in net profit for FY25 but maintained steady distributions, underpinned by key portfolio exits and a resilient US private equity market.

Fintech Chain Limited reported a 24% revenue increase to RMB55.9 million for FY2025 driven by new SaaS products, yet it remains in the red with a net loss of RMB4.8 million. The company has also applied for delisting from the ASX.

Delta Lithium Limited has announced a proposed demerger involving an in-specie distribution of over 63 million Ballard Mining shares to eligible shareholders, pending approval at a June 30 meeting. This move will reduce Delta's stake in Ballard and set the stage for Ballard's eventual ASX listing.

Excite Technology Services reported a strong 53% revenue increase to $12.27 million for FY2025 but also saw its net loss nearly double to $4.44 million. The company expanded its footprint with the acquisition of digital forensics specialist CBIT Pty Ltd.

Betashares Capital Ltd has announced the final distribution amounts for May 2025 for a suite of 16 ETFs listed on the ASX AQUA market, all franked and eligible for reinvestment via the Distribution Reinvestment Plan.

Credit Intelligence Ltd is set to return up to AU$1 million to shareholders following the sale of a significant asset, pending shareholder approval and completion of the disposal.

Credit Intelligence Ltd has announced a conditional agreement to sell its loss-making subsidiary Credit Intelligence Holding Limited for AUD 1.5 million, pending shareholder approval and regulatory clearances.

Papyrus Australia has secured a pivotal contract with UniSA to establish a Rapid Prototyping and R&D facility, advancing its sustainable packaging technology and commercial production plans.

Papyrus Australia reported a $52,000 operating cash outflow for April 2025 but bolstered its liquidity with $239,000 in financing inflows, extending its funding runway to over a year.

Amplia Therapeutics reports strong progress in its pancreatic cancer drug development, completing the ACCENT trial recruitment ahead of schedule and initiating a new US trial, while managing a $6.57 million loss for FY25.